Examining how robots are moving from demonstrations to daily use.
Updated
January 28, 2026 5:53 PM
An industrial robotic arm capable of autonomous welding. PHOTO: ADOBE STOCK
CES 2026 did not frame robotics as a distant future or a technological spectacle. Instead, it highlighted machines designed for the slow, practical work of fitting into human systems. Across the show floor, robots were no longer performing for attention but being shaped by real-world constraints—space, safety, fatigue and repetition.
They appeared in factories, homes, emergency settings and industrial sites, each responding to a specific kind of human limitation. Together, these four robots reveal how robotics is being redefined: not as a replacement for people, but as infrastructure that quietly takes on work humans are least meant to carry alone.
Hyundai Motor unveiled its electric humanoid robot, Atlas, during a media day on January 5, 2026, at the Mandalay Bay Convention Center in Las Vegas as part of CES 2026. Developed with Boston Dynamics, Hyundai’s U.S.-based robotics subsidiary, Atlas was presented in two forms: a research prototype and a commercial model designed for real factory environments.
Shown under the theme “AI Robotics, Beyond the Lab to Life: Partnering Human Progress,” Atlas is designed to work alongside humans rather than replace them. The premise is straightforward—robots take on physically demanding and repetitive tasks such as sorting and assembly, while people focus on work requiring judgment, creativity and decision-making.
Built for industrial use, the commercial version of Atlas is designed to adapt quickly, with Hyundai stating it can learn new tasks within a day. Its adult-sized humanoid form features 56 degrees of freedom, enabling flexible, human-like movement. Tactile sensors in its hands and a 360-degree vision system support spatial awareness and precise operation.
Atlas is also engineered for demanding conditions. It can lift up to 50 kilograms, operate in temperatures ranging from –20°C to 40°C and is waterproof, making it suitable for challenging factory settings.
Looking ahead, Hyundai expects Atlas to begin with parts sorting and sequencing by 2028, move into assembly by 2030 and later take on precision tasks that require sustained physical effort and focus.
Widemount’s Smart Firefighting Robot is designed to operate in environments that are difficult and dangerous for humans to enter. Developed by Widemount Dynamics, a spinout from the Hong Kong Polytechnic University, the robot is built to support emergency teams during fires, particularly in enclosed and smoke-filled spaces.
The robot can move through buildings and industrial facilities even when visibility is near zero. Rather than relying on cameras or GPS, it uses radar-based mapping to understand its surroundings and determine a safe path forward. This allows it to continue operating when smoke, heat or debris would normally restrict access.
As it approaches a fire, the robot analyses the burning object. Its onboard AI helps identify the material involved and selects an appropriate extinguishing method. Sensors simultaneously assess flame intensity and send real-time updates to command centres, giving responders clearer situational awareness.
When actively fighting a fire, the robot can aim directly at the source and deploy extinguishing agents autonomously. The system continuously adjusts its actions based on incoming sensor data, reducing the need for constant human intervention during high-risk situations.
At CES 2026, LG Electronics offered a glimpse into how household work could gradually shift from people to machines. The company introduced LG CLOiD, an AI-powered home robot designed to manage everyday chores by working directly with connected appliances within LG’s ThinQ ecosystem.
Designed for indoor living spaces, CLOiD features a compact upper body with two articulated arms, a head unit and a wheeled base that enables steady movement across floors. Its torso can tilt to adjust height, allowing it to reach items placed low or on kitchen counters. The arms and hands are built for careful handling, enabling the robot to grip common household objects rather than heavy tools. The head also functions as a mobile control unit, housing cameras, sensors, a display and voice interaction capabilities for communication and monitoring.
In practice, CLOiD acts as a task coordinator. It can retrieve items from appliances, operate ovens and washing machines and manage laundry cycles from start to finish, including folding and stacking clothes. By connecting multiple devices through the ThinQ system, the robot turns separate appliances into a single, coordinated workflow.
These capabilities are supported by LG’s Physical AI system. CLOiD uses vision to recognise objects and interpret its surroundings, language processing to understand instructions and action control to execute tasks step by step. Together, these systems allow the robot to follow routines, respond to user input and adjust task execution over time.
Doosan Robotics introduced Scan & Go at CES 2026, an AI-driven robotic system designed to automate large-scale surface repair and inspection. The solution targets environments with complex, irregular surfaces that are difficult to pre-program, such as aircraft structures, wind turbine blades and large industrial installations.
Scan & Go operates by scanning surfaces on site and building an understanding of their shape in real time. Instead of relying on detailed digital models or manual coding, the system plans its movements based on live data. This enables it to adapt to variations in size, curvature and surface condition without extensive setup.
The underlying technology combines 3D sensing with AI-based motion planning. The system interprets surface data, generates tool paths and refines its actions as work progresses. In practical terms, this reduces manual intervention while maintaining consistency across large work areas.
By handling surface preparation and inspection tasks that are time-consuming and physically demanding, Scan & Go is positioned as a support tool for industrial teams operating at scale.
Taken together, these robots signal a clear shift in how machines are being designed and deployed. Across factories, homes, emergency sites and industrial infrastructure, robotics is moving beyond demonstrations and into practical roles that support human work.
The unifying theme is not replacement, but relief—robots taking on tasks that are repetitive, hazardous or physically demanding. CES 2026 suggests that robotics is evolving from spectacle to utility, with a growing focus on systems that adapt to real environments, respond to genuine constraints and integrate into everyday workflows.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.